Hepatitis C Virus Vaccine: Challenges and Prospects

The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute in...

Full description

Bibliographic Details
Main Authors: Joshua D. Duncan, Richard A. Urbanowicz, Alexander W. Tarr, Jonathan K. Ball
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/8/1/90
id doaj-fedb316bb3e04d3c8d452d19e1b9c2e4
record_format Article
spelling doaj-fedb316bb3e04d3c8d452d19e1b9c2e42020-11-25T02:18:24ZengMDPI AGVaccines2076-393X2020-02-01819010.3390/vaccines8010090vaccines8010090Hepatitis C Virus Vaccine: Challenges and ProspectsJoshua D. Duncan0Richard A. Urbanowicz1Alexander W. Tarr2Jonathan K. Ball3School of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKThe hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.https://www.mdpi.com/2076-393X/8/1/90hepatitis c virusvaccinesneutralising antibodiesanimal modelsimmune responses
collection DOAJ
language English
format Article
sources DOAJ
author Joshua D. Duncan
Richard A. Urbanowicz
Alexander W. Tarr
Jonathan K. Ball
spellingShingle Joshua D. Duncan
Richard A. Urbanowicz
Alexander W. Tarr
Jonathan K. Ball
Hepatitis C Virus Vaccine: Challenges and Prospects
Vaccines
hepatitis c virus
vaccines
neutralising antibodies
animal models
immune responses
author_facet Joshua D. Duncan
Richard A. Urbanowicz
Alexander W. Tarr
Jonathan K. Ball
author_sort Joshua D. Duncan
title Hepatitis C Virus Vaccine: Challenges and Prospects
title_short Hepatitis C Virus Vaccine: Challenges and Prospects
title_full Hepatitis C Virus Vaccine: Challenges and Prospects
title_fullStr Hepatitis C Virus Vaccine: Challenges and Prospects
title_full_unstemmed Hepatitis C Virus Vaccine: Challenges and Prospects
title_sort hepatitis c virus vaccine: challenges and prospects
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2020-02-01
description The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.
topic hepatitis c virus
vaccines
neutralising antibodies
animal models
immune responses
url https://www.mdpi.com/2076-393X/8/1/90
work_keys_str_mv AT joshuadduncan hepatitiscvirusvaccinechallengesandprospects
AT richardaurbanowicz hepatitiscvirusvaccinechallengesandprospects
AT alexanderwtarr hepatitiscvirusvaccinechallengesandprospects
AT jonathankball hepatitiscvirusvaccinechallengesandprospects
_version_ 1724882386070536192